Published in Proc Natl Acad Sci U S A on March 16, 1999
Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry (2004) 1.79
Shared and unique roles of CAP23 and GAP43 in actin regulation, neurite outgrowth, and anatomical plasticity. J Cell Biol (2000) 1.35
Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem (2011) 1.27
The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop (2010) 1.18
Skin anti-aging strategies. Dermatoendocrinol (2012) 1.05
Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J Physiol (2008) 1.04
Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat (2007) 1.02
Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol (2008) 1.00
Botulinum toxin treatment of extraocular muscles in rabbits results in increased myofiber remodeling. Invest Ophthalmol Vis Sci (2005) 0.95
Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children. Cent European J Urol (2012) 0.95
Alpha-latrotoxin rescues SNAP-25 from BoNT/A-mediated proteolysis in embryonic stem cell-derived neurons. Toxins (Basel) (2011) 0.93
Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells. PLoS One (2014) 0.92
Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol (2014) 0.91
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med (2013) 0.89
Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action. J Cutan Aesthet Surg (2008) 0.88
Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol (2014) 0.88
Sustained synaptic-vesicle recycling by bulk endocytosis contributes to the maintenance of high-rate neurotransmitter release stimulated by glycerotoxin. J Cell Sci (2010) 0.88
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
The Use of Botulinum Toxin Type A in Headache Treatment. Curr Treat Options Neurol (2002) 0.87
The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry (2004) 0.87
Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Rev Mol Diagn (2014) 0.85
Neurexins, neuroligins and LRRTMs: synaptic adhesion getting fishy. J Neurochem (2011) 0.85
Botulinum toxin: poisoning the spastic bladder and urethra. Rev Urol (2002) 0.85
Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing. PLoS One (2011) 0.83
Acute and long-term effects of botulinum neurotoxin on the function and structure of developing extraocular muscles. Neurobiol Dis (2007) 0.83
Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J Pharmacol Exp Ther (2009) 0.83
Adult neuron addition to the zebra finch song motor pathway correlates with the rate and extent of recovery from botox-induced paralysis of the vocal muscles. J Neurosci (2011) 0.82
Presynaptic NCAM is required for motor neurons to functionally expand their peripheral field of innervation in partially denervated muscles. J Neurosci (2014) 0.81
The use of botulinum toxin in paediatric hypertonia. Paediatr Child Health (2005) 0.80
Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle. Invest Ophthalmol Vis Sci (2011) 0.80
Treatment of refractory anterior knee pain using botulinum toxin type A (Dysport) injection to the distal vastus lateralis muscle: a randomised placebo controlled crossover trial. Br J Sports Med (2010) 0.80
Systems analysis of transcriptional data provides insights into muscle's biological response to botulinum toxin. Muscle Nerve (2014) 0.80
Botulinum neurotoxin type-A enters a non-recycling pool of synaptic vesicles. Sci Rep (2016) 0.80
Temporal characteristics of botulinum neurotoxin therapy. Expert Rev Neurother (2010) 0.80
Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: case report and literature review. Dysphagia (2004) 0.80
Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections. Muscle Nerve (2015) 0.80
Botulinum toxin in paediatric urology: a systematic literature review. Pediatr Surg Int (2008) 0.79
Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity. Nephrourol Mon (2012) 0.79
Proteomic changes in rat gastrocnemius muscle after botulinum toxin a injection. Ann Rehabil Med (2013) 0.79
The influence of intravesical administration of resiniferatoxin (RTX) on the chemical coding of sympathetic chain ganglia (SChG) neurons supplying the porcine urinary bladder. Histochem Cell Biol (2015) 0.78
Persistence of Botulinum neurotoxin inactivation of nerve function. Curr Top Microbiol Immunol (2013) 0.78
Molecular mechanisms of treadmill therapy on neuromuscular atrophy induced via botulinum toxin A. Neural Plast (2013) 0.78
Endomicroscopy and electromyography of neuromuscular junctions in situ. Ann Clin Transl Neurol (2014) 0.78
The Role of Botulinum Toxin Type A in the Clinical Management of Refractory Anterior Knee Pain. Toxins (Basel) (2015) 0.77
Comparison of treatment effects between children with spastic cerebral palsy under and over five years after botulinum toxin type a injection. Ann Rehabil Med (2014) 0.77
Botulinum toxin pretreatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle. J AAPOS (2008) 0.77
Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr Top Med Chem (2014) 0.77
Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy. Arch Phys Med Rehabil (2009) 0.76
Early ultrasonographic evaluation of idiopathic clubfeet treated with manipulations, casts, and Botox(®): a double-blind randomized control trial. J Child Orthop (2015) 0.76
OnabotulinumtoxinA for chronic migraine: a critical appraisal. Ther Clin Risk Manag (2015) 0.76
Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection. Clin Interv Aging (2008) 0.76
Therapeutic Effect of Extracorporeal Shock Wave Therapy According to Treatment Session on Gastrocnemius Muscle Spasticity in Children With Spastic Cerebral Palsy: A Pilot Study. Ann Rehabil Med (2015) 0.76
Acrylamide inhibits nerve sprouting induced by botulinum toxin type A. Neural Regen Res (2014) 0.76
Effects of botulinum toxin serotype A on sleep problems in children with cerebral palsy and on mothers sleep quality and depression. Neurosciences (Riyadh) (2016) 0.75
Static balance and function in children with cerebral palsy submitted to neuromuscular block and neuromuscular electrical stimulation: study protocol for prospective, randomized, controlled trial. BMC Pediatr (2012) 0.75
Botulinum Toxin in Migraine Treatment. Noro Psikiyatr Ars (2013) 0.75
Snake and Spider Toxins Induce a Rapid Recovery of Function of Botulinum Neurotoxin Paralysed Neuromuscular Junction. Toxins (Basel) (2015) 0.75
Do nerve terminal sprouts contribute to functional recovery from botulinum neurotoxin A? J Physiol (2008) 0.75
The use of botulinum toxin and epidural analgesia for the treatment of spasticity and pain in a patient with maple syrup urine disease. Saudi J Anaesth (2012) 0.75
Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity. Drug Des Devel Ther (2016) 0.75
Combined effect of botulinum toxin and splinting on motor components and function of people suffering a stroke. Med J Islam Repub Iran (2016) 0.75
Characterizing the Bladder's Response to Onabotulinum Toxin Type A Using a Rat Model. Female Pelvic Med Reconstr Surg (2016) 0.75
Changes in Cerebellar Activation After Onabotulinumtoxin A Injections for Spasticity After Chronic Stroke: A Pilot Functional Magnetic Resonance Imaging Study. Arch Phys Med Rehabil (2015) 0.75
Botulinum Toxin Treatment for Limb Spasticity in Childhood Cerebral Palsy. Front Pharmacol (2016) 0.75
IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength. Int J Mol Sci (2013) 0.75
Cellular and Matrix Response of the Mandibular Condylar Cartilage to Botulinum Toxin. PLoS One (2016) 0.75
Pharmacotherapy for the management of achalasia: Current status, challenges and future directions. World J Gastrointest Pharmacol Ther (2015) 0.75
A literature review on the efficacy and safety of botulinum toxin: an injection in post-stroke spasticity. Int J Prev Med (2013) 0.75
Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays. PLoS One (2015) 0.75
Comparative Study of Efficacy and Safety of Botulinum Toxin a Injections and Subcutaneous Curettage in the Treatment of Axillary Hyperhidrosis. J Cutan Aesthet Surg (2017) 0.75
Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: A longitudinal study. Korean J Orthod (2017) 0.75
Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission. PLoS Pathog (2017) 0.75
Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study. Neurol Sci (2012) 0.75
Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. Curr Urol Rep (2017) 0.75
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature (1993) 5.73
Optical analysis of synaptic vesicle recycling at the frog neuromuscular junction. Science (1992) 4.56
Neurotrophins and neuronal plasticity. Science (1995) 4.53
The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol Cogn Med Sci (1968) 3.16
Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett (1993) 2.65
Visualization of neuromuscular junctions over periods of several months in living mice. J Neurosci (1987) 2.53
Imaging exocytosis and endocytosis. Curr Opin Neurobiol (1996) 2.41
Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry (1970) 2.25
Neurotrophin regulation of cortical dendritic growth requires activity. Neuron (1996) 2.08
An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci (1971) 1.92
Motor nerve sprouting. Annu Rev Neurosci (1981) 1.91
Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction. Trends Neurosci (1998) 1.86
Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry (1996) 1.77
In vivo visualization of the growth of pre- and postsynaptic elements of neuromuscular junctions in the mouse. J Neurosci (1990) 1.40
In vivo visualization of pre- and postsynaptic changes during synapse elimination in reinnervated mouse muscle. J Neurosci (1989) 1.39
Fluorescent probes that stain living nerve terminals. J Neurosci (1987) 1.36
Optical measurements of activity-dependent membrane recycling in motor nerve terminals of mammalian skeletal muscle. Proc Biol Sci (1994) 1.34
Characterization of the palmitoylation domain of SNAP-25. J Neurochem (1997) 1.33
Synaptic vesicle movements monitored by fluorescence recovery after photobleaching in nerve terminals stained with FM1-43. J Neurosci (1996) 1.28
Neurotransmitter release and synaptic vesicle recycling. Neuroscience (1990) 1.21
Induction of motor neuron sprouting in vivo by ciliary neurotrophic factor and basic fibroblast growth factor. J Neurosci (1992) 1.15
Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience (1990) 1.13
Intrinsic neuronal determinants that promote axonal sprouting and elongation. Bioessays (1997) 1.08
Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4. J Cell Biol (1994) 1.07
Presynaptic actions of botulinal neurotoxins at vertebrate neuromuscular junctions. J Physiol (Paris) (1990) 1.07
Synaptic plasticity in the mammalian central nervous system. Annu Rev Neurosci (1981) 1.01
Nerve growth in botulinum toxin poisoned muscles. Neuroscience (1981) 0.95
Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology (1991) 0.95
Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul Disord (1996) 0.94
The major 35S-methionine-labeled rapidly transported protein (superprotein) is identical to SNAP-25, a protein of synaptic terminals. J Neurosci (1991) 0.93
Elimination of superfluous neuromuscular junctions in rat calf muscles recovering from botulinum toxin-induced paralysis. Muscle Nerve (1994) 0.92
Mechanisms of postsynaptic plasticity: remodeling of the junctional acetylcholine receptor cluster induced by motor nerve terminal outgrowth. J Neurosci (1987) 0.85
Sprouting of mammalian motor nerve terminals induced by in vivo injection of botulinum type-D toxin and the functional recovery of paralysed neuromuscular junctions. Neurosci Lett (1993) 0.85
Synaptic transmission blockade increases plasminogen activator activity in mouse skeletal muscle poisoned with botulinum toxin type A. Synapse (1995) 0.82
Botulinum-induced changes in monkey eyelid muscle. Comparison with changes seen in extraocular muscle. Arch Ophthalmol (1991) 0.82
Inactivation properties of voltage-gated K+ channels altered by presence of beta-subunit. Nature (1994) 4.38
Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ (2007) 4.12
The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ (2009) 2.29
Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature (1984) 2.02
Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol (1986) 1.83
Acetylcholine receptor and ion conductance modulator sites at the murine neuromuscular junction: evidence from specific toxin reactions. Proc Natl Acad Sci U S A (1973) 1.82
Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry (1996) 1.77
Quantal acetylcholine release at the vertebrate neuromuscular junction. Physiol Rev (1994) 1.73
Central action of dendrotoxin: selective reduction of a transient K conductance in hippocampus and binding to localized acceptors. Proc Natl Acad Sci U S A (1986) 1.72
The structure and mode of action of different botulinum toxins. Eur J Neurol (2006) 1.51
Glial heterogeneity in expression of the inwardly rectifying K(+) channel, Kir4.1, in adult rat CNS. Glia (2000) 1.43
Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem (1992) 1.43
Primary structure of a beta subunit of alpha-dendrotoxin-sensitive K+ channels from bovine brain. Proc Natl Acad Sci U S A (1994) 1.34
Preparation and characterisation of homogeneous neurotoxin type A from Clostridium botulinum. Its inhibitory action on neuronal release of acetylcholine in the absence and presence of beta-bungarotoxin. Eur J Biochem (1982) 1.34
Vesicle exocytosis stimulated by alpha-latrotoxin is mediated by latrophilin and requires both external and stored Ca2+. EMBO J (1998) 1.28
Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol (1980) 1.28
Subunit combinations defined for K+ channel Kv1 subtypes in synaptic membranes from bovine brain. Biochemistry (1997) 1.27
Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry (1994) 1.27
Protein kinase B stimulates the translocation of GLUT4 but not GLUT1 or transferrin receptors in 3T3-L1 adipocytes by a pathway involving SNAP-23, synaptobrevin-2, and/or cellubrevin. J Biol Chem (1999) 1.25
Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes. Eur J Biochem (1983) 1.25
Binding of perhydro-histrionicotoxin to the postsynaptic membrane of skeletal muscle in relation to its blockage of acetylcholine-induced depolarization. Mol Pharmacol (1977) 1.24
The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience (1982) 1.24
Studies on the oestrogen sulphatase and arylsulphatase C activities of rat liver. Biochem J (1972) 1.22
Subunit composition of Kv1 channels in human CNS. J Neurochem (1999) 1.22
Antibodies specific for distinct Kv subunits unveil a heterooligomeric basis for subtypes of alpha-dendrotoxin-sensitive K+ channels in bovine brain. Biochemistry (1994) 1.20
The effects of pH and curare on the time course of end-plate currents at the neuromuscular junction of the frog. J Physiol (1978) 1.19
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture (2000) 1.19
Botulinum neurotoxin and dendrotoxin as probes for studies on transmitter release. J Physiol (Paris) (1984) 1.19
Oligomeric properties of alpha-dendrotoxin-sensitive potassium ion channels purified from bovine brain. Biochemistry (1992) 1.18
Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes. Eur J Biochem (1986) 1.17
Multiple forms of dipeptidases in normal human intestinal mucosa and in mucosa from children with coeliac disease. Clin Chim Acta (1969) 1.15
Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience (1990) 1.13
Two acceptor sub-types for dendrotoxin in chick synaptic membranes distinguishable by beta-bungarotoxin. Eur J Biochem (1986) 1.12
alpha subunit compositions of Kv1.1-containing K+ channel subtypes fractionated from rat brain using dendrotoxins. Eur J Biochem (1999) 1.11
Dendrotoxin acceptor from bovine synaptic plasma membranes. Binding properties, purification and subunit composition of a putative constituent of certain voltage-activated K+ channels. Biochem J (1989) 1.10
Preparation of neurotoxic 3H-beta-bungarotoxin: demonstration of saturable binding to brain synapses and its inhibition by toxin I. Eur J Biochem (1982) 1.08
Brain and muscle nicotinic acetylcholine receptors are different but homologous proteins. Proc Natl Acad Sci U S A (1985) 1.05
Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. J Neurochem (1988) 1.05
Stoichiometry of the ligand-binding sites in the acetylcholine-receptor oligomer from muscle and from electric organ. Measurement by affinity alkylation with bromoacetylcholine. Eur J Biochem (1980) 1.05
Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol (1986) 1.04
Discrepancies between spontaneous and evoked synaptic potentials at normal, regenerating and botulinum toxin poisoned mammalian neuromuscular junctions. Proc R Soc Lond B Biol Sci (1982) 1.04
Identification of residues in dendrotoxin K responsible for its discrimination between neuronal K+ channels containing Kv1.1 and 1.2 alpha subunits. Eur J Biochem (1999) 1.03
Mast cell degranulating peptide and dendrotoxin selectively inhibit a fast-activating potassium current and bind to common neuronal proteins. Neuroscience (1987) 1.03
Prominent location of a K+ channel containing the alpha subunit Kv 1.2 in the basket cell nerve terminals of rat cerebellum. Neuroscience (1993) 1.02
The wheat proteins puroindoline-a and alpha1-purothionin induce nodal swelling in myelinated axons. Neuroreport (1998) 1.01
Episodic ataxia type-1 mutations in the Kv1.1 potassium channel display distinct folding and intracellular trafficking properties. J Biol Chem (2001) 1.01
4-aminoquinoline-induced 'giant' miniature endplate potentials at mammalian neuromuscular junctions. Proc R Soc Lond B Biol Sci (1982) 1.00
The acetylcholine receptor and the ionic conductance modulation system of skeletal muscle. Exp Neurol (1975) 1.00
Complete purification of beta-bungarotoxin. Characterization of its action and that of tityustoxin on synaptosomal accumulation and release of acetylcholine. Biochim Biophys Acta (1980) 0.98
Metabolism of sodium oestrone ( 35 S)sulphate in the rat. Biochem J (1971) 0.98
Alpha-dendrotoxin acceptor from bovine brain is a K+ channel protein. Evidence from the N-terminal sequence of its larger subunit. J Biol Chem (1990) 0.97
Involvement of the constituent chains of botulinum neurotoxins A and B in the blockade of neurotransmitter release. Eur J Biochem (1988) 0.97
Nicotinic acetylcholine receptor from chick optic lobe. Proc Natl Acad Sci U S A (1982) 0.97
Involvement of neuronal acceptors for dendrotoxin in its convulsive action in rat brain. Biochem J (1986) 0.96
Botulinum A and the light chain of tetanus toxins inhibit distinct stages of Mg.ATP-dependent catecholamine exocytosis from permeabilised chromaffin cells. Eur J Biochem (1994) 0.96
A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Biochemistry (1994) 0.96
IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2. Cell Death Dis (2013) 0.95
Botulinum toxin and 4-aminoquinoline induce a similar abnormal type of spontaneous quantal transmitter release at the rat neuromuscular junction. Brain Res (1983) 0.95
Size of acetylcholine receptors in the membrane. An improved version of the radiation inactivation method. Biochemistry (1982) 0.94
Studies on the mode of action of botulinum toxin type A at the frog neuromuscular junction. Brain Res (1984) 0.94
Phosphoinositides as key regulators of synaptic function. Neuron (2001) 0.94
Cloning and functional expression of dendrotoxin K from black mamba, a K+ channel blocker. Biochemistry (1993) 0.93
Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. J Neurosci Res (1996) 0.93
A new type of transmitter release at the neuromuscular junction. Neuroscience (1983) 0.93
[Ciguatoxins and brevetoxins: dissection of the neurobiological actions]. J Soc Biol (1999) 0.92
Affinity labelling by bromoacetylcholine of a characteristic subunit in the acetylcholine receptor from muscle and Torpedo electric organ. FEBS Lett (1979) 0.91
Cadmium and the reticuloendothelial system (RES). A specific defect in blood clearance of soluble aggregates of IgG by the liver in mice given cadmium. Immunology (1980) 0.91
Norepinephrine exocytosis stimulated by alpha-latrotoxin requires both external and stored Ca2+ and is mediated by latrophilin, G proteins and phospholipase C. Philos Trans R Soc Lond B Biol Sci (1999) 0.90
A sensitive and useful radioimmunoassay for neurotoxin and its haemagglutinin complex from Clostridium botulinum. Toxicon (1985) 0.90
Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain. Proc Natl Acad Sci U S A (1988) 0.90
Similarity of acetylcholine receptors of denervated, innervated and embryonic chicken muscles. 2. Subunit compositions. Eur J Biochem (1982) 0.90
Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor. Br J Pharmacol (2009) 0.89
Characterization of monoclonal antibodies against voltage-dependent K+ channels raised using alpha-dendrotoxin acceptors purified from bovine brain. Biochemistry (1992) 0.89
Effects of botulinum neurotoxin and Lambert-Eaton myasthenic syndrome IgG at mouse nerve terminals. J Neural Transm Park Dis Dement Sect (1989) 0.89
Latrophilin, neurexin, and their signaling-deficient mutants facilitate alpha -latrotoxin insertion into membranes but are not involved in pore formation. J Biol Chem (2000) 0.89
Modification of rat brain Kv1.4 channel gating by association with accessory Kvbeta1.1 and beta2.1 subunits. Pflugers Arch (1997) 0.89
Outcome of acetylcholinesterase deficiency for neuromuscular functioning. Neurosci Res (2006) 0.88
Dendrotoxin, 4-aminopyridine, and beta-bungarotoxin act at common loci but by two distinct mechanisms to induce Ca2+-dependent release of glutamate from guinea-pig cerebrocortical synaptosomes. J Neurochem (1989) 0.88
Effects of Anemonia sulcata toxin II on presynaptic currents and evoked transmitter release at neuromuscular junctions of the mouse. Pflugers Arch (1985) 0.88
Identification by cross-linking of a neuronal acceptor protein for dendrotoxin, a convulsant polypeptide. FEBS Lett (1984) 0.88
Properties of monoclonal antibodies to nicotinic acetylcholine receptor from chick muscle. Eur J Biochem (1984) 0.88
Lipid dynamics in exocytosis. Cell Mol Neurobiol (2010) 0.88
Nicotinic acetylcholine receptors: an overview. Biochem Pharmacol (1984) 0.88
Complete purification of the acetylcholine receptor protein from mammalian muscle. FEBS Lett (1975) 0.88
Acetylcholine and GABA receptors: subunits of central and peripheral receptors and their encoding nucleic acids. Cold Spring Harb Symp Quant Biol (1983) 0.87
Cloning of a bovine voltage-gated K+ channel gene utilising partial amino acid sequence of a dendrotoxin-binding protein from brain cortex. FEBS Lett (1992) 0.87
Solubilization from skeletal muscle of two components that specifically bind -bungarotoxin. Biochem Biophys Res Commun (1973) 0.87
Interactions between discrete neuronal membrane binding sites for the putative K+-channel ligands beta-bungarotoxin, dendrotoxin and mast-cell-degranulating peptide. Eur J Biochem (1989) 0.87
Production of seizures and brain damage in rats by alpha-dendrotoxin, a selective K+ channel blocker. Neurosci Lett (1992) 0.87
Distribution in the rat central nervous system of acceptor sub-types for dendrotoxin, a K+ channel probe. Neuroscience (1989) 0.87
Preferential action of beta-bungarotoxin at nerve terminal regions in the hippocampus. Neurosci Lett (1982) 0.87
Dynamic control of neuroexocytosis by phosphoinositides in health and disease. Prog Lipid Res (2010) 0.87
Putative benzodiazepine receptor: a protein solubilised from brain. FEBS Lett (1979) 0.87
Further studies on multiple forms of peptidases in mammalian tissues including intestinal mucosa from children with treated and untreated coeliac disease. Clin Chim Acta (1971) 0.86
The timing of channel opening during miniature endplate currents at the frog and mouse neuromuscular junctions: effects of fasciculin-2, other anti-cholinesterases and vesamicol. Pflugers Arch (1994) 0.86
Botulinum neurotoxin - from laboratory to bedside. Neurotox Res (2006) 0.86